SCHEMBL4582434

SCHEMBL4582434

Cc1cccc(-c2cc(F)cnc2N)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 2/20 0.49
FYN P06241 7/20 0.46
MAP4K4 O95819 3/20 0.46
CHEK1 O14757 1/20 0.46
ABL1 P00519 1/20 0.46
NTRK1 P04629 1/20 0.46
LCK P06239 1/20 0.46
CSF1R P07333 1/20 0.46
MET P08581 1/20 0.46
PDGFRB P09619 1/20 0.46
PIM1 P11309 1/20 0.46
FGFR1 P11362 1/20 0.46
PDGFRA P16234 1/20 0.46
PRKACA P17612 1/20 0.46
LTK P29376 1/20 0.46
GRK5 P34947 1/20 0.46
KDR P35968 1/20 0.46
FLT3 P36888 1/20 0.46
MAPK8 P45983 1/20 0.46
CSNK1A1 P48729 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20288103 0.85 CYP2A6 (0.57) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL4580922 0.81 MAP4K4 (0.54) FYNMAP4K4ABL1PDGFRBKDR
SCHEMBL29857982 0.81 ADORA1 (0.49) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL4582430 0.81 CHEK2 (0.44) FYNMAP4K4CHEK2
SCHEMBL12516853 0.81 ADORA1 (0.49) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL27227708 0.77 PDGFRB (0.50) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL4582784 0.75 MAP4K4 (0.69) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL4470993 0.73 CHEK2 (0.56) FYNMAP4K4KMT2ACHEK2MEN1
SCHEMBL1388276 0.72 ADORA1 (0.70) ADORA1FYNMAP4K4CHEK1ABL1
SCHEMBL30488016 0.72 ADORA1 (0.70) ADORA1FYNMAP4K4CHEK1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362017-B2 N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening EXELIXIS, INC. (US) 2013-01-29 US disclosed
US-20080096892-A1 C-Kit Modulators And Methods Of Use EXELIXIS, INC. (US) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080096892-A1 C-Kit Modulators And Methods Of Use KIT, PRKCH, PRKCB ADORA1 1637/4885FYN 1657/4885MAP4K4 354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.